Tests a stomach acid drug to protect the esophagus during lung cancer radiation
Tests a daily acid-reducing drug to prevent esophagitis in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy
Key facts
- Where
- London, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- London Health Sciences CentreLondon, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT07076914
- Record updated
- 22 July 2025
- Original description
A randomized controlled trial to assess the impact of prophylactic proton pump inhibitor use to improve esophagitis in lung cancer patients undergoing radiation. Patients will be randomized into a standard of care arm or the prophylactic proton pump (daily) arm.Read full original descriptionShow less
Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy: A Randomized Clinical Trial
A randomized controlled trial to assess the impact of prophylactic proton pump inhibitor use to improve esophagitis in lung cancer patients undergoing radiation. Patients will be randomized into a standard of care arm or the prophylactic proton pump (daily) arm.
Inclusion: Age 18 years or older; Willing to provide informed consent; Eastern Cooperative Oncology Group (ECOG) performance status 0-3; Life expectancy of at least 3 months; Primary lung malignancy of any stage (including NSCLC and small cell lung cancer). Histologic/pathologic diagnosis is preferred, but not required; Receiving a prescribed dose of at least 40 Gy in 15 fractions (or equivalent). Eligible fractionations include, but are not limited to, 60 Gy in 30 fractions, 55 Gy in 20 fractions, and 40-45 Gy in 15 fractions; On radiation planning, at least 5 cc of esophagus is receiving at least 95% of prescription dose.
Exclusion: • Serious medical comorbidities precluding radiotherapy; Use of PPI within 3 months prior to enrollment; Allergy to PPI; Odynophagia (painful swallowing) prior to enrollment; Pregnant or lactating women; Note: previous radiation to the thorax is allowed, as long as the composite plan of current and prior radiation doses meet standard institutional dose constraints, in the opinion of the treating radiation oncologist.